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The implementation of transfusion guidelines in patients with cirrhosis remains 
challenging, as the over-permissive practice of decades conflicts with emerging 
clinical data on the need and efficacy of both prophylactic and therapeutic 
transfusions.  
Our understanding of coagulopathy in cirrhosis has significantly changed in the last 
decade and landmark publications have proved that cirrhosis is not a 
hypocoagulable state (1). Indeed, both pro- and anticoagulant factors are decreased 
and the haemostatic balance, although maintained, is set at a lower point (2). The 
relative deficiency of both coagulation system drivers results in a fragile balance that 
is easily tipped towards haemorrhage or thrombosis, depending on circumstantial 
risk factors such as bleeding, infection or renal failure (3). Patients with cirrhosis are 
not  “auto-anticoagulated” but on the contrary have an increase risk of unprovoked 
venous thromboembolism compared to general population controls (4). 
In vitro studies have shown that thrombin generation is impaired in patients with 
cirrhosis only when the platelet count drops to <50x109/L (5). Therefore conventional 
coagulation tests, such as prothrombin time (PT), do not reflect the bleeding 
tendency in such patients and cannot be used to guide transfusion decisions. A 
meta-analysis of the prophylactic use of fresh frozen plasma (FFP) prior to invasive 
procedures, showed that red blood cell (RBC) transfusion requirements are not 
reduced in patients with chronic liver disease (6).  
Moreover, even in the setting of variceal bleeding, over-transfusion of RBCs is 
associated with a worse outcome, probably due to an increase in the portal pressure 
and further bleeding. In a randomised controlled trial of 921 patients with severe 
acute upper gastrointestinal bleeding (AUGIB), a restrictive transfusion strategy 
(transfusion when the haemoglobin <7 g/dl) was associated with reduced further 
bleeding, fewer adverse events and improved survival compared to a liberal strategy 
(transfusion when the hemoglobin <9 g/dl) (7). Remarkably, the probability of survival 
was higher with the restrictive strategy than with the liberal strategy in the subgroup 
of patients with Child–Pugh class A or B cirrhosis (hazard ratio 0.30), while the 
portal-pressure gradient increased significantly in those patients assigned to the 
liberal but not in those assigned to the restrictive strategy (7). Following the results of 
this study, the recent Baveno VI (8) and United Kingdom (UK) guidelines (9)  for the 
management of variceal bleeding recommend that red blood cells transfusion should 
be done conservatively at a target haemoglobin level between 7 and 8 g/dl, although 
transfusion policies in individual patients should also consider additional factors such 
as cardiovascular disorders, age, hemodynamic status and on-going bleeding. 
Although no recommendation was made for the management of coagulopathy, the 
Baveno VI guidelines state that PT/INR is not a reliable indicator of the coagulation 
status in patients with cirrhosis (8).  
Despite these advances in our understanding of coagulopathy and bleeding risk in 
cirrhosis, there is a significant lag in clinical practice as evidenced by the nationwide 
UK audit by Desborough and co-authors (10). Data on 1313 consecutive patients 
with cirrhosis were collected from 85 hospitals in a 28-day period. In the entire 
cohort, 391/1313 (30%) of patients were transfused at least one blood component 
during their admission, which is a striking figure and is comparable to cohorts 
admitted in intensive care or undergoing major surgical procedures. Of these, 61% 
received transfusion for treatment and 39% for prophylaxis of bleeding. For those 
transfused with RBCs for treatment of AUGIB, the pre-transfusion threshold was 
>80g/L in 48/185 (26%) cases and >70g/L (restrictive threshold used in the 
Barcelona trial of transfusion strategies for AUGIB (7)) in 82/185 (44%). Transfusion 
for prophylaxis in the absence of bleeding was given in 153/1313 (12%) of patients; 
in this category, 20/101 (20%) of patients had a pre-transfusion haemoglobin >80g/L 
and 58/101 (57%) had a pre-transfusion haemoglobin >70g/L. For patients 
transfused with FFP, 32/81 (40%) had a pre-transfusion INR of <1.5, which 
represents an arbitrary cut-off level for high-risk procedures. Of particular concern is 
the fact that a minority of patients received FFP and platelets empirically, in the 
absence of a planned procedure or bleeding.  Thrombosis or thromboembolic 
disease occurred in 35/1313 (3%) cases including deep vein thrombosis, splanchnic 
vein thrombosis and pulmonary embolism and were the same in transfused and non-
transfused patients.  
This nationwide audit convincingly demonstrates that a very significant proportion of 
blood transfusions in patients with cirrhosis are unjustified and potentially harmful. 
The potential reasons and solutions for this differ between therapeutic and 
prophylactic transfusions. As far as the management of transfusion requirements in 
upper GI bleeding is concerned, this study has demonstrated that the adherence to 
existing national and international guidelines is poor. This could be due to the fact 
that patients with cirrhosis who bleed present to emergency departments and are 
initially treated by the acute medical team with delayed input from hepatology. Acute 
bleeding in patients with cirrhosis and coagulation abnormalities still triggers massive 
transfusion protocols that can actually do more harm than good. The British 
Association for the Study of the Liver recently issued a decompensated cirrhosis 
care bundle with a checklist to be completed within the first 6 hours of admission 
(11). Similar guidelines from international societies could inform other specialties and 
improve the acute care of liver patients. 
As far as the prophylactic use of products is concerned, there are no evidence-based 
guidelines, as the in vitro data of thrombin generation in cirrhosis have not been 
translated in clinical trials to date. The wide variation in clinical practice reflects the 
need for further studies on coagulation in cirrhotic patients in various clinical settings 
with multiple co-factors taken into account, in order to identify accurate markers to 
predict the status of the coagulation imbalance in these patients.  A recently 
published pilot randomised study examined the efficacy and safety of 
thromboelastography (TEG) in guiding the use of FFP or platelet transfusion before 
invasive procedures in patients with cirrhosis and impaired traditional coagulation 
tests (12). Despite the use of a conservative TEG threshold, only 5/30 patients in the 
TEG group received blood product transfusions as compared to all patients (30/30) 
in the standard of care group. Most notably, post-procedure bleeding occurred in 
only one patient in the standard of care group and none in the TEG group. Although 
most patients had low risk procedures and these results will require further 
validation, this study addressed an unmet clinical need and provided important proof-
of-concept insights. Further adequately powered studies are warranted, potentially 
using thrombin generation assays, in order to conclusively identify the subgroup of 
patients with cirrhosis who need prophylactic administration of blood products prior 
to an invasive procedure.  
It is therefore time that the liver community sufficiently communicates that cirrhosis is 
not an acquired bleeding disorder. Robust internationally accepted guidelines on 
transfusion policies in cirrhotic patients will result in this increased awareness, will 
identify areas of uncertainty and facilitate trials to resolve them.  
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